Edgewood Management
HOWL icon

Edgewood Management’s Werewolf Therapeutics HOWL Stock Holding History

Edgewood Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$31.7K – 89
2025
Q4 		$31.7K Hold
50,000
– – ﹤0.01% 89
2025
Q3 		$98.5K Hold
50,000
– – ﹤0.01% 88
2025
Q2 		$54.5K Hold
50,000
– – ﹤0.01% 83
2025
Q1 		$48.6K Hold
50,000
– – ﹤0.01% 84
2024
Q4 		$74K Hold
50,000
– – ﹤0.01% 83
2024
Q3 		$106K Hold
50,000
– – ﹤0.01% 78
2024
Q2 		$122K Hold
50,000
– – ﹤0.01% 79
2024
Q1 		$324K Hold
50,000
– – ﹤0.01% 71
2023
Q4 		$193K Hold
50,000
– – ﹤0.01% 78
2023
Q3 		$107K Hold
50,000
– – ﹤0.01% 78
2023
Q2 		$153K Hold
50,000
– – ﹤0.01% 79
2023
Q1 		$130K Buy
+50,000
New +$149K ﹤0.01% 81

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Edgewood Management's HOWL Position: Q1 2026 in Review

Edgewood Management sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 50,000 shares — an estimated $31.7K sold.

Edgewood Management first reported a position in HOWL in Q1 2023 and held it in 12 quarters. The position peaked at $324K in Q1 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Edgewood Management reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Edgewood Management sold 50,000 Werewolf Therapeutics shares in Q1 2026, an estimated $31.7K.
  • Edgewood Management first reported a position in Werewolf Therapeutics in Q1 2023 and held it in 12 quarters.
  • Edgewood Management's Werewolf Therapeutics position peaked at $324K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Edgewood Management's 13F filing for Q1 2026, filed 14 May 2026.